Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2026 Jan 9;41(1):23.
doi: 10.1007/s00384-025-05060-z.

Preoperative chemotherapy for colon cancer and short-term outcomes-a nationwide cohort study

M Delorme  1 , E Agger  2 , F Jörgren  3 , M L Lydrup  2 , H Hagman  4 , P Buchwald  2
Affiliations

Preoperative chemotherapy for colon cancer and short-term outcomes-a nationwide cohort study

M Delorme et al. Int J Colorectal Dis. .

Abstract

Purpose: High-risk colon cancer may benefit from preoperative chemotherapy (preCHT), but evidence on its short-term safety and outcome is limited. Population-based evidence before its incorporation into national guidelines is lacking.

Methods: Patients with final weighted stage II-III colon cancer undergoing elective resection between 2007 and 2017 were identified in the Swedish Colorectal Cancer Registry. Patients planned for preCHT, irrespective of intention, were compared with those undergoing upfront surgery. Primary outcomes were 30- and 90-day mortality and 30-day major morbidity, defined as all medical and surgical complications classified as Clavien-Dindo (CD) ≥ 3 grade. Subgroup analyses examined cT4 disease, and multivariable logistic regression was performed.

Results: Among 20,185 eligible patients, 299 (1.5%) received preCHT. Postoperative mortality was comparable (1.7% vs. 1.7%, p = 1.00 at 30 days and 3.0% vs. 2.8%, p = 0.82 at 90 days). Overall and surgical postoperative morbidity (CD ≥ 3) was higher in the preCHT group (34.1 vs. 25.0%, p < 0.001 and 17.4% vs. 13.1%, p < 0.001), rates of anastomotic leakage were similar (3.3% vs. 3.6%, p = 0.85). Compared to upfront surgery, the preCHT group was more likely to undergo multivisceral resections (53.9% vs. 13.6%, p < 0.001), with a higher rate of R1 resections (6.4% vs. 3.2%, p < 0.001), reflecting more advanced disease (cT4: 59.5% vs. 10.5%, p < 0.001; cN1-2: 54.9% vs. 28.6%, p < 0.001). In the cT4 subgroup, short-term outcomes were comparable, and regression analyses found no independent association between preCHT and mortality or major morbidity.

Conclusion: PreCHT appeared feasible in cT4N0-2M0 colon cancer, with short-term outcomes comparable to upfront surgery despite more advanced primary tumour and greater surgical extent.

Keywords: Colon cancer; Morbidity; Mortality; Neoadjuvant treatment; Preoperative chemotherapy; Short-term outcomes.

PubMed Disclaimer

Conflict of interest statement

Declarations. Consent to participate: All patients have consented to participate in the Swedish Colorectal Cancer Registry. Ethics approval: Ethical approval to conduct the study was granted by the Swedish Ethical Review Authority (2023–00810-02). Competing interests: The authors declare no competing interests. Prior submission: The abstract has been submitted for presentation at the Swedish Surgical Week 2025 in Linköping, Sweden (19–23 August 2025).

Figures

Fig. 1
Fig. 1
Study flow chart. preCHT, preoperative chemotherapy; NRT, neoadjuvant chemoradiotherapy
See this image and copyright information in PMC

References

    1. Hohenberger W, Weber K, Matzel K et al (2009) Standardized surgery for colonic cancer: Complete mesocolic excision and central ligation - technical notes and outcome. Colorectal Dis 11:354–364. 10.1111/j.1463-1318.2008.01735.x - DOI - PubMed
    1. Benson AB, Schrag D, Somerfield MR et al (2004) American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 22:3408–3419 - DOI - PubMed
    1. Hendren S, Birkmeyer JD, Yin H et al (2010) Surgical complications are associated with omission of chemotherapy for stage III colorectal cancer. Dis Colon Rectum 53:1587–1593. 10.1007/DCR.0b013e3181f2f202 - DOI - PubMed
    1. Biagi JJ, Raphael MJ, Mackillop WJ et al (2011) Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer a systematic review and meta-analysis. JAMA 305:2335–2342 - DOI - PubMed
    1. Osterman E, Glimelius B (2018) Recurrence risk after up-to-date colon cancer staging, surgery, and pathology: analysis of the entire Swedish population. Dis Colon Rectum 61:1016–1025. 10.1097/DCR.0000000000001158 - DOI - PubMed

LinkOut - more resources